Format

Send to

Choose Destination
Nat Biotechnol. 2016 Apr;34(4):430-4. doi: 10.1038/nbt.3461. Epub 2016 Feb 22.

Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.

Author information

1
Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
2
Department of Medicine, University of Washington, Seattle, Washington, USA.
3
Institute for Advanced Study, Technical University of Munich, Munich, Germany.

Abstract

Adoptive immunotherapy with genetically engineered T cells has the potential to treat cancer and other diseases. The introduction of Strep-tag II sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors of diverse specificities provides engineered T cells with a marker for identification and rapid purification, a method for tailoring spacer length of chimeric receptors for optimal function, and a functional element for selective antibody-coated, microbead-driven, large-scale expansion. These receptor designs facilitate cGMP manufacturing of pure populations of engineered T cells for adoptive T-cell therapies and enable in vivo tracking and retrieval of transferred cells for downstream research applications.

PMID:
26900664
PMCID:
PMC4940167
DOI:
10.1038/nbt.3461
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center